Oral agents and Outpatient Injections
FUNDING:
Take-home cancer drugs are covered by the New Brunswick Drug Plans for eligible beneficiaries. Patients not covered by the New Brunswick Drug Plans may have private insurance coverage.
FORMULARIES:
New Brunswick Drug Plans Formulary: Click Here
Drug (Brand Name) Manufacturer |
Indication | Strength, Route | DIN | Provincial Funding Eligibility Criteria | References | Patient Assistance Programs |
---|---|---|---|---|---|---|
Abiraterone (Zytiga) Janssen Inc. Generic | mCRPC | 250 mg tab | 500 mg tab |
Multiple |
Special Authorization Criteria Eligibility:
Renewal Criteria:
Clinical Notes:
Claim Notes:
|
|
Janssen (Janssen BioAdvance Patient Assistance Program): Access Here |
Abiraterone (Zytiga) Janssen Inc. Generic | mCSPC | 250 mg tab | 500 mg tab |
Multiple |
Special Authorization Criteria Eligibility:
Renewal Criteria:
Clinical Notes:
Claim Notes:
|
|
Janssen (Janssen BioAdvance Patient Assistance Program): Access Here |
Alendronate Generic | Osteoporosis | 10 mg Tab | 70 mg PO |
Multiple |
Regular benefit |
|
Apotex: Access Here |
Apalutamide (Erleada) Janssen Inc. | nmCRPC | Tablet, PO, 60mg, 240mg |
02478374 |
Special Authorization Criteria Eligibility:
Renewal Criteria:
Clinical Notes:
Claim Notes:
**60 mg tablet funded, 240 mg tablet pending provincial funding decision |
|
Janssen BioAdvance Patient Assistance Program: Access Here
|
Apalutamide (Erleada) Janssen Inc. | mCSPC | Tablet, PO, 60mg, 240mg |
02478374 |
Special Authorization Criteria Eligibility:
Renewal Criteria:
Clinical Notes:
Claim Notes:
**60 mg tablet funded, 240 mg tablet pending provincial funding decision |
|
Janssen BioAdvance Patient Assistance Program: Access Here |
Darolutamide (Nubeqa) Bayer | nmCRPC | 300 mg Tab |
02496348 |
Special Authorization Criteria Eligibility:
Renewal Criteria:
Clinical Notes:
Claim Notes:
|
|
NUBEQA® DART Patient Support Program: Toll free: 1-833-955-3278 Fax: 1-877-208-4393 Email:
|
Darolutamide (Nubeqa) Bayer | mCSPC | 300mg Tab |
02496348 |
Special Authorization Criteria
Eligibility: In combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) who have had no prior ADT, or are within 6 months of beginning ADT, in the metastatic setting.
Renewal Criteria:
Clinical Notes:
Claim Notes:
|
NUBEQA® DART Patient Support Program: Toll free: 1-833-955-3278 Fax: 1-877-208-4393 Email: |
|
Denosumab (Prolia) Amgen | Osteoporosis | 60 mg / ml |
02343541 |
Special Authorization Criteria Eligibility:
Clinical Notes:
|
|
ProVital Program: Access Here |
Denosumab (Prolia) Amgen | mCRPC + Bone mets | 120 mg / 1.7 ml vial |
02368153 |
Special Authorization Criteria Eligibility:
* patients who are asymptomatic and those who are symptomatic and in bed less than 50% of the time |
|
The VICTORY Program: Access Here |
Enzalutamide (Xtandi) Astellas | mCRPC | 40 mg capsule |
02407329 |
For the treatment of patients with metastatic castration-resistant prostate cancer.
Renewal Criteria:
Clinical Notes:
Claim Notes:
|
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (French)
|
|
Enzalutamide (Xtandi) Astellas | nmCRPC | 40 mg capsule |
02407329 |
Non-Metastatic Castration-Resistant Prostate Cancer In combination with androgen deprivation therapy (ADT) for the treatment of patients with non-metastatic castration-resistant prostate cancer who have a prostate-specific antigen (PSA) doubling time of less than or equal to 10 months during continuous ADT (i.e., high risk of developing metastases).
Renewal Criteria:
Clinical Notes:
Claim Notes:
|
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (French)
|
|
Enzalutamide (Xtandi) Astellas | mCSPC | 40 mg capsule |
02407329 |
In combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) who have had no prior ADT, or are within 6 months of beginning ADT, in the metastatic setting.
Renewal Criteria:
Clinical Notes:
Claim Notes:
|
Xtandi Patient Assistance Program (XPAP): Patient Enrolment and Consent Form (English) Formulaire D’inscription et de Consentement du Patient (French)
|
|
Niraparib and abiraterone acetate (AKEEGA®) Janssen Inc. | mCRPC | Dual-action tablet, PO/ Comprimé à double action, PO: 100mg niraparib/500mg abiraterone acetate |
02538563 |
Pending provincial funding decision |
N/A |
Janssen BioAdvance Patient Assistance Program: Access Here |
Olaparib (Lynparza) AstraZeneca | mCRPC | 100 mg tab | 150 mg tab |
100mg: 02475200 | 150mg: 02475219 |
For the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who meet all of the following criteria:
|
AstraZeneca Patient Support Program: Access Here |